Bregua Corp - 10 Jun 2021 Form 3 Insider Report for Janux Therapeutics, Inc. (JANX)

Role
10%+ Owner
Signature
/s/ Klaus Dorner, Director of Bregua Corporation
Issuer symbol
JANX
Transactions as of
10 Jun 2021
Net transactions value
$0
Form type
3
Filing time
10 Jun 2021, 19:32:26 UTC
Next filing
16 Jun 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding JANX Series Seed Convertible Preferred Stock 10 Jun 2021 Common Stock 1,138,665 Direct F1, F2
holding JANX Series Seed 2 Convertible Preferred Stock 10 Jun 2021 Common Stock 1,630,428 Direct F1, F2
holding JANX Series A Convertible Preferred Stock 10 Jun 2021 Common Stock 674,211 Direct F1, F2
holding JANX Series B Convertible Preferred Stock 10 Jun 2021 Common Stock 247,123 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Series Seed Convertible Preferred Stock, Series Seed 2 Convertible Preferred Stock, Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") is convertible into 1.281 shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock has no expiration date.
F2 These securities are held directly by Bregua Corporation (Bregua). Klaus Dorner is the Director of Bregua and may be deemed to have voting and investment power with respect to the shares held by Bregua and as a result may be deemed to have beneficial ownership of such shares. Mr. Dorner disclaims beneficial ownership of all shares held by Bregua, except to the extent of his actual pecuniary interest therein, if any.